NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé îíêîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Armstrong GT, Kawashima T, Leisenring W, et al: Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study, J Clin Oncol 32(12):1218–1227, 2014.
Centers for Disease Control and Prevention: Cancer death rates for children and teens aged 1–19 years — United States, 1999, 2006, and 2014, MMWR 65(41):1153, 2015.
Chen M, Chang CH, Tao L, Lu C: Residential exposure to pesticide during childhood and childhood cancers: a meta-analysis, Pediatrics 136(4):719–729, 2015.
Howlader N, Noone AM, Krapcho M, et al, editors: SEER cancer statistics review, 1975–2014, Bethesda, MD, 2016, National Cancer Institute. SEER data submission, SEER website, April 2017. http://seer.cancer.gov/csr/1975_2014/.
Mathews JD, Forsythe AV, Brady Z, et al: Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million australians, BMJ 346:f2360, 2013.
Miller KD, Siegel RL, Lin CC, et al: Cancer treatment and survivorship statistics, 2016, CA Cancer J Clin 66(4):271–289, 2016.
Porter CC, Druley TE, Erez A, et al: Recommendations for surveillance for children with leukemia-predisposing conditions, Clin Cancer Res 23(11):e14–e22, 2017.
Siegel DA, Henley SJ, Li J, et al: Rates and trends of pediatric acute lymphoblastic leukemia — United States, 2001–2004, MMWR 66(36):950–954, 2017.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017, CA Cancer J Clin 67(1):7–30, 2017.
Smith MA, Altekruse SF, Adamson PC, et al: Declining childhood and adolescent cancer mortality, Cancer 120:2497–2506, 2014.
Steliarova-Foucher E, Columbet M, Ries LAG, et al: International incidence of childhood cancer, 2001–10: a population-based registry study, Lancet Oncol 18:719–731, 2017.
Ward E, DeSantis C, Robbins A, et al: Childhood and adolescent cancer statistics, 2014, CA Cancer J Clin 64(2):83–103, 2014.
Yanik EL, Smith JM, Shiels MS, et al: Cancer risk after pediatric solid organ transplantation, Pediatrics 139(5):e20163893, 2017.
Yu TM, Chuang YW, Yu MC, et al: Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study, Lancet Oncol 17(10):1419–1425, 2016.
Arndt GM, MacKenzie KL: New prospects for targeting telomerase beyond the telomere, Nat Rev Cancer 16:508–524, 2016.
Belver L, Ferrando A: The genetics and mechanisms of T cell acute lymphoblastic leukaemia, Nat Rev Cancer 16:494–507, 2016.
Evans DG: Genetic predisposition to cancer, Medicine (Baltimore) 44(1):65–68, 2015.
Mandelker D, Zhang L, Kemel Y, et al: Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing, JAMA 318(9):825–835, 2017.
Maris JM: Defining why cancer develops in children, N Engl J Med 373(24):2373–2374, 2015.
Mertens F, Johansson B, Fioretos T, et al: The emerging complexity of gene fusions in cancer, Nat Rev Cancer 15:371–381, 2015.
Mussa A, Molinatto C, Baldassarre G, et al: Cancer risk in Beckwith-wiedemann syndrome: a systematic review and meta-analysis outlining a novel (Epi)genotype specific histotype targeted screening protocol, J Pediatr 176:142–149, 2016.
Roberts KG, Mullighan CG: Genomics in acute lymphoblastic leukaemia: insights and treatment implications, Nat Rev Clin Oncol 12:344–357, 2015.
Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes, Science 339:1546–1558, 2013.
Young LS, Yap LF, Murray PG: Epstein-barr virus: more than 50 years old and still providing surprises, Nat Rev Cancer 16:789–802, 2016.
Zhang J, Walsh MF, Wu G, et al: Germline mutations in predisposition genes in pediatric cancer, N Engl J Med 373:2336–2346, 2015.
Allen NM, McKeon A, O’Rourke DJ, et al: Excessive blinking and ataxia in a child with occult neuroblastoma and voltage-gated potassium channel antibodies, Pediatrics 129(5):e1348–e1352, 2012.
Atkin KL, Ditchfield MR: The role of whole-body MRI in pediatric oncology, J Pediatr Hematol Oncol 36(5):342–351, 2014.
Franco A, Mody NS, Meza MP: Imaging evaluation of pediatric mediastinal masses, Radiol Clin North Am 43(2):325–353, 2005.
Guillerman RP, McCarville ME, Kaste SC, et al: Imaging studies in the diagnosis and management of pediatric malignancies. In Pizzo PA, Poplack DG, editors: Principles and practice of pediatric oncology, ed 6, Philadelphia, 2011, Lippincott Williams & Wilkins, pp 216–277.
Kilburn LB, Malogolowkin MH, Quinn JJ, et al: Clinical assessment and differential diagnosis of the child with suspected cancer. In Pizzo PA, Poplack DG, editors: Principles and practice of pediatric oncology, ed 6, Philadelphia, 2011, Lippincott Williams & Wilkins, pp 123–137.
Pynnonen MA, Gillespie MB, Roman B, et al: Clinical practice guideline: evaluation of the neck mass in adults, Otolaryngol Head Neck Surg 157(2S):S1–S30, 2017.
Sinniah D, D’Angio GJ, Chatten J, et al: Atlas of pediatric oncology, London, 1996, Arnold.
Triche TJ, Hicks J, Sorensen PHB: Diagnostic pathology of pediatric malignancies. In Pizzo PA, Poplack DG, editors: Principles and practice of pediatric oncology, ed 6, Philadelphia, 2011, Lippincott Williams & Wilkins, pp 164–215.
Armenian SH, Robison LL: Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects, Curr Opin Pediatr 25(1):16–22, 2013.
Armstrong GT, Chen Y, Yasui Y, et al: Reduction in late mortality among 5-year survivors of childhood cancer, N Engl J Med 374(9):833–842, 2016.
Asselin BL, Devidas M, Chen L, et al: Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: a report of the Children’s oncology group randomized trial pediatric oncology group 9404, J Clin Oncol 34:854–862, 2015.
Bakshi S, Batra A, Biswas B, et al: Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial, Support Care Cancer 23:3229–3237, 2015.
Barone A, Rubin JB: Opportunities and challenges for successful use of bevacizumab in pediatrics, Front Oncol 3:1–12, 2013.
Barrett DM, Teachey DT, Grupp SA: Toxicity management for patients receiving novel T-cell engaging therapies, Curr Opin Pediatr 26(1):43–49, 2014.
Bartholomew F, Aftandilian C, Andrews J, et al: Evaluation of febrile, nonneutropenic pediatric oncology patients with central venous catheters who are not given empiric antibiotics, J Pediatr 166:157–162, 2015.
Bhakta N, Liu Q, Ness KK, et al: The cumulative burden of surviving childhood cancer: an initial report from the st. Jude lifetime cohort study (SJLIFE), Lancet 390(10112):2569–2582, 2017.
De Fine Licht S, Winther JF, Gudmundsdottir T, et al: Hospital contacts for endocrine disorders in adult life after childhood cancer in scandinavia (ALiCCS): a populationbased cohort study, Lancet 383:1981–1989, 2014.
Dupuis LL, Boodhan S, Holdsworth M, et al: Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients, Pediatr Blood Cancer 60:1073–1082, 2013.
Filippi F, Meazza C, Paffoni A, et al: Egg freezing in childhood and young adult cancer survivors, Pediatrics 138(4):e20160291, 2016.
Fong SL, van den Heuvel-Eibrink MM, Eijkemans MJC, et al: Pregnancy outcome in female childhood cancer survivors, Hum Reprod 25:1206–1212, 2010.
Giulino LB, Bussel JB, Neufeld EJ, et al: Treatment with rituximab in benign and malignant hematologic disorders in children, J Pediatr 150:338–344, 2007.
Green DM, Kawashima T, Stovall M, et al: Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study, J Clin Oncol 27:2677–2685, 2009.
Henry M, Sung L: Supportive care in pediatric oncology, Pediatr Clin North Am 62(1):27–46, 2015.
Hershman DL: Scalp cooling to prevent chemotherapy-induced alopecia: the time has come, JAMA 317(6):587–588, 2017.
Holmquist AS, Olsen JH, Mellemkjaer L, et al: Autoimmune diseases in adult life after childhood cancer in scandinavia (ALiCCS), Ann Rheum Dis 75(9):1622–1629, 2016.
Howard SC, Jones DP, Pui CH: The tumor lysis syndrome, N Engl J Med 364(19):1844–1854, 2011.
Hudson MM, Ness KK, Gurney JG, et al: Clinical ascertainment of health outcomes among adults treated for childhood cancer, JAMA 309(22):2371–2381, 2013.
Jackson HJ, Rafiq S, Brentjens RJ: Driving CAR T-cells forward, Nature 13:370–383, 2016.
Kane CM, Hoskin P, Bennett MI: Cancer induced bone pain, BMJ 350:h176, 2015.
Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med 362:2260–2270, 2010.
Kearns P, Morland B: New drug development in childhood cancer, Curr Opin Pediatr 26(1):37–42, 2014.
Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol 33:540–549, 2014.
Kun LE: General principles of radiation oncology. In Pizzo PA, Poplack DG, editors: Principles and practice of pediatric oncology, ed 6, Philadelphia, 2011, Lippincott Williams & Wilkins, pp 406–425.
Kurt BA, Armstrong GT, Cash KC, et al: Primary care management of the childhood cancer survivor, J Pediatr 152:458–466, 2008.
Kurtz BP, Abrams AN: Psychiatric aspects of pediatric cancer, Pediatr Clin North Am 58(4):1003–1023, xii, 2011.
Lauritano D, Petruzzi M, Di Stasio D, Lucchese A: Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study, Int J Oral Sci 6:27–30, 2014.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastomic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet 385:517–528, 2015.
Lehrnbecher T, Phillips R, Alexander S, et al: Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation, J Clin Oncol 30:4427–4438, 2012.
McCabe MS, Partridge A, Grunfeld E, Hudson MM: Risk-based health care, the cancer survivor, the oncologist, and the primary care physician, Semin Oncol 40:804–812, 2013.
The Medical Letter: Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting, Med Lett Drugs Ther 7(1467):61–64, 2015.
Mhaskar R, Clark OA, Lyman G, et al: Colony-stimulating factors for chemotherapyinduced febrile neutropenia, Cochrane Database Syst Rev (10):CD003039, 2014.
Merchant TE, Farr JB: Proton beam therapy: a fad or a new standard of care?, Curr Opin Pediatr 26(1):3–8, 2014.
Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort, BMJ 339:b4606, 2009.
Navari RM, Aapro M: Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting, N Engl J Med 374(14):1356–1366, 2016.
Oeffinger KC, Ford JS, Moskowitz CS, et al: Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer, JAMA 301:404–414, 2009.
Pati?o-Garc?a A, Zalaca?n M, Marrod?n L, et al: Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression, J Pediatr 154:688–693, 2009.
Poirot C, Abirached F, Prades M, et al: Induction of puberty by autograft of cryopreserved ovarian tissue, Lancet 379(9815):588, 2012.
Pollock BH, Tomlinson GE: Preventing cancer in adulthood: advice for the pediatrician. In Pizzo PA, Poplack DG, editors: Principles and practice of pediatric oncology, ed 6, Philadelphia, 2011, Lippincott Williams & Wilkins, pp 1474–1488.
Portenoy RK: Treatment of cancer pain, Lancet 377(9784):2236–2247, 2011.
Reulen RC, Frobisher C, Winter DL, et al: British childhood cancer survivor study steering group: long-term risks of subsequent primary neoplasms among survivors of childhood cancer, JAMA 305(22):2311–2319, 2011.
Reulen RC, Winter DL, Frobisher C, et al: Long-term cause-specific mortality among survivors of childhood cancer, JAMA 304:172–178, 2010.
Robinson PD, Lehrnbecher T, Phillips R, et al: Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials, J Clin Oncol 34:2054–2060, 2016.
Roser MH, Perazella MA: Acute kidney injury in patients with cancer, N Engl J Med 376(18):1770–1780, 2017.
Ross CJD, Katzov-Eckert H, Dub? MP, et al: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy, Nat Genet 41:1345–1349, 2009.
Smith MA, Altekruse SF, Adamson PC, et al: Declining childhood and adolescent cancer mortality, Cancer 120(16):2497–2506, 2014.
Soussain C, Ricard D, Fike JR, et al: CNS complications of radiotherapy and chemotherapy, Lancet 374:1639–1650, 2009.
Stanworth SJ, Estcourt LJ, Powter G, et al: TOPPS investigators: a no-prophylaxis platelettransfusion strategy for hematologic cancers, N Engl J Med 368(19):1771–1780, 2013.
Turcotte LM, Liu Q, Yasui Y, et al: Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970–2015, JAMA 317(18):814–824, 2017.
Van Casteren NJ, van der Linden GHM, Hakvoort-Cammel GAJ, et al: Effect of childhood cancer treatment on fertility markers in adult male long-term survivors, Pediatr Blood Cancer 52:108–112, 2009.
Viswanathan AN: Childhood cancer survivors: stillbirth and neonatal death, Lancet 376:570–572, 2010.
Wallace WH, Thompson L, Anderson RA: Guideline development group: long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance, BMJ 346:f1190, 2013.
Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al: Hydrocortisone as an intervention for dexamethasone-induced adverse effects in pediatric patients with acute lymphoblastic leukemia: results of a double-blind, randomized controlled trial, J Clin Oncol 34:2287–2293, 2016.
Wayne AS, Capitini CM, Mackall CL: Immunotherapy of childhood cancer: from biologic understanding to clinical application, Curr Opin Pediatr 22:2–11, 2010.
Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma, N Engl J Med 363:1324–1334, 2010.
Aoki T, Koh K, Arakawa Y, et al: Reversible cerebral vasoconstriction syndrome during chemotherapy for acute lymphoblastomic leukemia, J Pediatr 180:284, 2017.
Armstrong GT, Chen Y, Yasui Y, et al: Reduction in late mortality among 5-year survivors of childhood cancer, N Engl J Med 374(9):833–842, 2016.
Asselin BL, Devidas M, Chen L, et al: Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: a report of the Children’s oncology group randomized trial pediatric oncology group 9404, J Clin Oncol 34(6):854–862, 2015.
Bhatia S: Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors, Pediatrics 130:1141–1143, 2012.
Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s oncology group study, Blood 111:5477–5485, 2008.
Brix N, Rosth?j S, Herlin T, Hasle H: Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children, Arch Dis Child 100:821–825, 2015.
Carroll WL, Raetz EA: Clinical and laboratory biology of childhood acute lymphoblastic leukemia, J Pediatr 160:10–18, 2012.
Clarke RT, Van den Bruel A, Bankhead C, et al: Clinical presentation of childhood leukaemia: a systematic review and meta-analysis, Arch Dis Child 101:894–901, 2016.
Claudio J, Rocha C, Cheng C, et al: Pharmacogenetics of outcome in children with acute lymphoblastic leukemia, Blood 105:4752–4758, 2005.
Diller L: Adult primary care after childhood acute lymphoblastic leukemia, N Engl J Med 365:1417–1424, 2011.
Diouf B, Crews KR, Lew G, et al: Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia, JAMA 313(8):815–823, 2015.
Greaves M: In utero origins of childhood leukaemia, Early Hum Dev 81:123–129, 2005.
Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med 368(16):1509–1518, 2013.
Guest EM, Stam RW: Updates in the biology and therapy for infant acute lymphoblastic leukemia, Curr Opin Pediatr 29:20–26, 2017.
Hijiya N, Hudson MM, Lensing S, et al: Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia, JAMA 297:1207–1215, 2007.
Hochberg J, Khaled S, Forman SJ, et al: Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission, Br J Haematol 161:27–42, 2013.
Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s oncology group, J Clin Oncol 30:1663–1669, 2012.
Hunger SP, Mullighan CG: Acute lymphoblastic leukemia in children, N Engl J Med 373:1541–1552, 2015.
Jackson HJ, Rafiq S, Brentjens RJ: Driving CAR T-cells forward, Nature 13:370–383, 2016.
Jacola LM, Edelstein K, Liu W, et al: Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the childhood cancer survivor study, Lancet Psychiatry 3:965–972, 2016.
Kantarjian HM, DeAngelo DJ, Stelljes M, et al: Inotuzumab ozogamiein versus standard therapy for acute lymphoblastic leukemia, N Engl J Med 375(8):740–752, 2016.
Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet 385:517–528, 2015.
Leung W, Pui CH, Coustan-Smith E, et al: Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia, Blood 120(2):468–472, 2012.
Mullighan CG, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia, N Engl J Med 360:470–480, 2009.
Patel SR, Ortin M, Cohen BJ, et al: Revaccination of children after completion of standard chemotherapy for acute leukemia, Clin Infect Dis 44:635–642, 2007.
Pui CH, Campana D, Pei D, et al: Treating childhood acute lymphoblastic leukemia without cranial irradiation, N Engl J Med 360:2730–2740, 2009.
Pui CH, Carroll WL, Meshinchi S, et al: Biology, risk stratification, and therapy of pediatric acute leukemias: an update, J Clin Oncol 29:551–565, 2011.
Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?, Blood 120:1165–1174, 2012.
Pui CH, Yang JJ, Hunger SP, et al: Childhood acute lymphoblastic leukemia: progress through collaboration, J Clin Oncol 33:2938–2948, 2015.
Ram R, Wolach O, Vidal L, et al: Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis, Am J Hematol 87:472–478, 2012.
Schafer ES, Hunger SP: Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults, Nat Rev Clin Oncol 8:417–424, 2011.
Schrappe M, Hunger SP, Pui CH, et al: Outcomes after induction failure in childhood acute lymphoblastic leukemia, N Engl J Med 366:1371–1381, 2012.
Schultz KR, Carroll A, Heerema NA: Long-term follow-up of imatinib in pediatric philadelphia chromosome–positive acute lymphoblastic leukemia: Children’s oncology group study AALL0031, Leukemia 28:1467–1471, 2014.
Shaw PJ, Kan F, Ahn KW, et al: Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors, Blood 116(19):4007–4015, 2010.
Siegel DA, Henley J, Li J, et al: Rates and trends of pediatric acute lymphoblastic leukemia — United States, 2001–2014, MMWR Morb Mortal Wkly Rep 66(36):950–954, 2017.
Stanulla M, Schaeffeler E, Flohr T, et al: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia, JAMA 293:1485–1489, 2005.
Stock W, La M, Sanford B, et al: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s cancer group and cancer and leukemia group B studies, Blood 112:1646–1654, 2008.
Temming P, Jenney MEM: The neurodevelopmental sequelae of childhood leukemia and its treatment, Arch Dis Child 95:936–940, 2010.
Arber DA, Orazi A, Hasserjian R, et al: The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia, Blood 127:2391–2405, 2016.
De Thi H: Lessons taught by acute promyelocytic leukemia cure, Lancet 386:247–248, 2015.
Fernandez HF, Sun Z, Yai X, et al: Anthracycline dose intensification in acute myeloid leukemia, N Engl J Med 361:1249–1259, 2009.
Gamis AS, Alonzo TA, Perentesis JP, et al: On behalf of the COG acute myeloid leukemia committee (2013): Children’s oncology Group’s 2013 blueprint for research: acute myeloid leukemia, Pediatr Blood Cancer 60:964–971, 2013.
Ivey A, Hills RK, Simpson MA, et al: Assessment of minimal residual disease in standard-rick AML, N Engl J Med 374(5):422–432, 2016.
Lo-Coco F, Avvisati G, Vignetti M: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia, N Engl J Med 369:111–121, 2013.
Niewerth D, Creutzig U, Bierings MB, et al: A review on allogenic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia, Blood 30:2205–2214, 2010.
Patel JP, G?nen M, Figueroa ME, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N Engl J Med 366(12):1079–1089, 2012.
Rizzari C, Cazzaniga G, Coliva T, et al: Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease, Expert Rev Anticancer Ther 11:1391–1401, 2011.
Ross ME, Mahfouz R, Onciu M, et al: Gene expression profiling of pediatric acute myelogenous leukemia, Blood 104:3679–3687, 2004.
Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N Engl J Med 358:1909–1918, 2008.
Swerdlow SH, Campo E, Harris NL, et al: WHO classification of tumours of haematopoietic and lymphoid tissue, ed 4, Lyons, 2008, International Agency for Research in Cancer.
Tarlock K, Meshinchi S: Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants, Pediatr Clin North Am 62:75–93, 2015.
Zwaan CM, Kolb EA, Reinhardt D, et al: Collaborative efforts driving progress in pediatric acute myeloid leukemia, J Clin Oncol 33:2949–2962, 2015.
Bercovich D, Ganmore I, Scott LM, et al: Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome, Lancet 372:1484–1492, 2008.
Cushing T, Clericuzio C, Wilson C, et al: Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder, J Pediatr 148:687–689, 2006.
Iwashita N, Sadahira C, Yuza Y, et al: Vesiculopustular eruption in neonate with trisomy 21 and transient myeloproliferative disorder, J Pediatr 162(3):643–644, 2013.
Izraeli S: The acute lymphoblastic leukemia of down syndrome: genetics and pathogenesis, Eur J Med Genet 59:158–161, 2016.
Maloney KW, Taub JW, Ravindranath Y, et al: Down syndrome: preleukemia and leukemia, Pediatr Clin North Am 62:121–137, 2015.
Sorrell AD, Alonzo TA, Hilden JM, et al: Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on Children’s oncology group trial a2971: a report from the Children’s oncology group, Cancer 118:4806–4814, 2012.
Xavier AC, Ge Y, Taub J: Unique clinical and biological features of leukemia in down syndrome children, Expert Rev Hematol 3:175–186, 2010.
Champagne MA, Fu CH, Chang M, et al: Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children’s oncology group, Pediatr Blood Cancer 57:56–62, 2011.
Hijiya N, Millot F, Suttorp M: Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions, Pediatr Clin North Am 62:107–119, 2015.
Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and philadelphia chromosome–positive ALL, N Engl J Med 354:2542–2550, 2006.
Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med 362(24):2260–2270, 2010.
Mahon FX, R?a D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial, Lancet Oncol 11:1029–1035, 2010.
Saglio G, Kim DN, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N Engl J Med 362(24):2251–2256, 2010.
Suttorp M, Eckardt L, Tauer JT, et al: Management of chronic myeloid leukemia in childhood, Curr Hematol Malig Rep 7:116–124, 2012.
Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant philadelphia chromosome–positive leukemias, N Engl J Med 354:2531–2540, 2006.
Loh ML: Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia, Br J Haematol 152:677–687, 2011.
Loh ML, Mullighan CG: Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy, Clin Cancer Res 18:2754–2767, 2012.
Niemeyer CM, Kang MW, Shin DH, et al: Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia, Nat Genet 42:794–800, 2010.
Woods WG, Barnard DR, Alonzo TA, et al: Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome, J Clin Oncol 20:434–440, 2002.
Yoshimi A, Kojima S, Hirano N: Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations, Paediatr Drugs 12: 11–21, 2010.
Greaves M: In utero origins of childhood leukaemia, Early Hum Dev 81:123–129, 2005.
Guest EM, Stam RW: Updates in the biology and therapy for infant acute lymphoblastic leukemia, Curr Opin Pediatr 29:20–26, 2017.
Hunger SP, Loh KM, Baker KS, et al: Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia, Biol Blood Marrow Transplant 15:79–83, 2009.
Isoda T, Ford AM, Tomizawa D, et al: Immunologically silent cancer clone transmission from mother to offspring, Proc Natl Acad Sci USA 106:17882–17885, 2009.
Pieters R, Schrappe M, De Lorenzo P, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomized trial, Lancet 370:240–250, 2007.
Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N Engl J Med 372(4):311–319, 2015.
Bollard CM, Rooney CM, Heslop HE: T-cell therapy in the treatment of post-transplant lymphoproliferative disease, Nat Rev Clin Oncol 9:510–519, 2012.
Cairo MS, Woessmann W, Pagel J: Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas, Biol Blood Marrow Transplant 19(1 Suppl):S38–S43, 2013.
Casanovas O, Coiffier B: Hodgkin’s lymphoma: better outcomes with fewer drugs?, Lancet 385:1371–1373, 2015.
Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification, J Clin Oncol 32(27):3059–3067, 2014.
Johnson P, Federico M, Kirkwood A, et al: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma, N Engl J Med 374:2419–2429, 2016.
Kelly KM: Hodgkin lymphoma in children and adolescents: improving the therapeutic index, Blood 126:2452–2458, 2015.
Satwani P, Jin Z, Martin PL, et al: Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent hodgkin and non-hodgkin lymphoma, Leukemia 29(2):448–455, 2015.
Schaapveld M, Aleman BMP, van Eggermond AM, et al: Second cancer risk up to 40 years after treatment of Hodgkin’s lymphoma, N Engl J Med 373(26):2499–2510, 2015.
Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma, N Engl J Med 362:875–885, 2010.
Westin JR, Chu F, Zhang M, et al: Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, Lancet Oncol 15:69–77, 2014.
Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma, J Clin Oncol 30(18):2183–2189, 2012.
Younes A, Oki Y, McLaughlin P, et al: Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical hodgkin lymphoma, Blood 119(18):4123–4128, 2012.
Burkhardt B, Mueller S, Khanam T, Perkins SL: Anaplastic large cell lymphoma in paediatric and young adult patients, Br J Haematol 173(4):545–559, 2016.
Cairo MS, Pinkerton R: Childhood, adolescent and young adult non-hodgkin lymphoma: state of the science, Br J Haematol 173(4):507–530, 2016.
Cairo MS, Sposto R, Gerrard M, et al: Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (?15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-hodgkin’s lymphoma: results of the FAB LMB 96 study, J Clin Oncol 30(4):387–393, 2012.
Cairo MS, Woessmann W, Pagel J: Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas, Biol Blood Marrow Transplant 19(1 Suppl):S38–S43, 2013.
Galardy PJ, Hochberg J, Perkins SL, et al: Rasburicase in the prevention of laboratory/clinical tumor lysis syndrome in children with advanced mature B-NHL: a Children’s oncology group report, Br J Haematol 163(3):365–372, 2013.
Gerrard M, Waxman IM, Sposto R, et al: French-American-British/lymphome malins de burkitt 96 (FAB/LMB 96) international study committee. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy, Blood 121(2):278–285, 2013.
Goldman S, Smith L, Anderson JR, et al: Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-hodgkin lymphoma: a Children’s oncology group report, Leukemia 27:1174–1177, 2013.
Goldman S, Smith L, Galardy P, et al: Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow positive burkitt lymphoma/leukaemia, Br J Haematol 167(3):394–401, 2014.
Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol 33:540–549, 2014.
Maciejka-Kemblowska L, Chaber R, Wrobel G, et al: Clinical features and treatment outcomes of peripheral T-cell lymphoma in children: a current data report from Polish pediatric Leukemia/lymphoma study group (PPLLSG), Adv Med Sci 61:311–316, 2016.
Miles RR, Arnold S, Cairo MS: Risk factors and treatment of childhood and adolescent burkitt lymphoma/leukaemia, Br J Haematol 156(6):730–743, 2012.
Turner SD, Lamant L, Kenner L, Brugieres L: Anaplastic large cell lymphoma in paediatric and young adult patients, Br J Haematol 173(4):560–572, 2016.
Ater JL, Xia C, Mazewski CM, et al: Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children’s oncology group, Cancer 122:1928–1936, 2016.
Brown CE, Alizadah D, Starr R, et al: Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med 375(26):2561–2569, 2016.
Buczkowicz P, Hoeman C, Rakopoulos P, et al: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations, Nat Genet 46:451–456, 2014.
Gajjar A, Bowers DC, Karajannis MA, et al: Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape, J Clin Oncol 33(27):2986–2998, 2015.
Gautier A, Godbout A, Grosheny C, et al: Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients, J Clin Endocrinol Metab 97(4):1258–1267, 2012.
Geoerger B, Blockus H: Everolimus for astrocytomas in tuberous sclerosis complex, Lancet 381(9861):95–96, 2013.
Jakola AS, Myrmel KS, Kloster R, et al: Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas, JAMA 308(18):1881–1888, 2012.
Jalali R, Gupta T, Goda JS, et al: Efficacy of stereotactic conformal radiotherapy vs conventional radiotherapy on benign and low-grade brain tumors, JAMA Oncol 3(10):1368–1376, 2017.
Johann PD, Serap E, Zapatka M, et al: Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgraoups with distinct enhancer landscapes, Cancer Cell 29:379–393, 2016.
Jones C, Karajannis MA, Jones DT, et al: Pediatric high-grade glioma: biologically and clinically in need of new thinking, Neuro Oncol 19(2):153–161, 2017.
Khatua S, Ramaswamy V, Bouffet E, et al: Current therapy and the evolving molecular landscape of paediatric ependymoma, Eur J Cancer 70:34–41, 2017.
Murray MJ, Bartels U, Nishikawa R, et al: Consensus on management of intracranial germ-cell tumours, Lancet Oncol 16(9):e470–e477, 2015.
Netson KL, Ashford JM, Skinner T, et al: Executive dysfunction is associated with poorer health-related quality of life in pediatric brain tumor survivors, J Neurooncol 128:313–321, 2016.
Okita Y, Narita Y, Miyakita Y, et al: Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed?, Clin Neurol Neurosurg 114:1217–1221, 2012.
Ostrom QT, Gittleman H, Fulop J, et al: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012, Neuro Oncol 17:iv1–iv62, 2015.
Parasramka S, Talari G, Rosenfeld M, et al: Procarbazine, lomustine and vincristine for recurrent high-grade glioma (review), Cochrane Database Syst Rev (7):CD011773, 2017.
Ramaswamy V, Remke M, Bouffet E, et al: Risk stratification of childhood medulloblastoma in the molecular era: the current consensus, Acta Neuropathol 131:821–831, 2016.
Sampson JH: Alternating electric fields for the treatment of glioblastoma, JAMA 314(23):2511–2513, 2015.
Stupp R, Taillbert S, Kanner AA, et al: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial, JAMA 314(23):2535–2543, 2015.
Thomas C, Sill M, Ruland V, et al: Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups, Neuro Oncol 18(6):790–796, 2016.
Vitanza NA, Cho YJ: Advances in the biology and treatment of pediatric central nervous system tumors, Curr Opin Pediatr 28:34–39, 2016.
Vossough A: Exploring long-term neurologic complications with advanced imaging in pediatric brain tumor survivors, J Pediatr 185:6–7, 2017.
Alaghband P, Long V: Periorbital ecchymosis, J Pediatr 168:245, 2016.
Arakawa A, Oguma E, Aihara A, et al: Long-term follow-up results of the observation program for neuroblastoma detected at 6-month mass screening, J Pediatr 165:855–857, 2014.
Bagatell R, Cohn SL: Genetic discoveries and treatment advances in neuroblastoma, Curr Opin Pediatr 28:19–25, 2016.
Bresler SC, Weiser DA, Huwe PJ, et al: ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma, Cancer Cell 26:682–694, 2014.
Decarolis B, Scheider C, Hero B, et al: Iodine-123 metaiodobenzylguanine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the cologne interscore comparative study, J Clin Oncol 31:944–951, 2013.
DuBois SG, Marachelian A, Fox E, et al: Phase 1 study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial, J Clin Oncol 34:1368–1375, 2016.
Pinto NR, Applebaum MA, Volchenboum SL, et al: Advances in risk classification and treatment strategies for neuroblastoma, J Clin Oncol 33(27):3008–3017, 2015.
Ploessi C, Pan A, Maples KT, Lowe DK: Dinutuximab: an anti-GD-2 monoclonal antibody for high risk neuroblastoma, Ann Pharmacother 50:416–422, 2016.
Pugh TJ, Morozova O, Attiyeh EF, et al: The genetic landscape of high-risk neuroblastoma, Nat Genet 45:279–284, 2013.
Ratner N, Brodeur GM, Russell CD, et al: The “neuro” of neuroblastoma: neuroblastoma as a neurodevelopment disorder, Ann Neurol 80:13–23, 2016.
Seif AE, Naranjo A, Baker DL, et al: A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s oncology group study ANBL00p1, Bone Marrow Transplant 48(7):947–952, 2013.
Suh M, Park HY, Choi SS, et al: Case report of PET/CT imaging of a patient with neuroblastoma using 18f-FPBG, Pediatrics 134(6): e1731–e1734, 2014.
Williams P, Wegner E, Ziegler DS: Outcomes in multifocal neuroblastoma as part of the neurocristopathy syndrome, Pediatrics 134: e611–e616, 2014.
Von Allmen D, Davidoff AM, London WB, et al: Impact of extent of resection on local control and survival in patients from the COG A3973 study with high risk neuroblastoma, J Clin Oncol 35:208–216, 2017.
Ahmed HU, Arya M, Levitt G, et al: Part I. Primary malignant non-wilms’ renal tumours in children, Lancet Oncol 8:730–737, 2007.
Ahmed HU, Arya M, Levitt G, et al: Part II: treatment of primary malignant non-wilms’ renal tumours in children, Lancet Oncol 8:842–848, 2007.
Ali AN, Diaz R, Shu HK, et al: A surveillance, Epidemiology and end results (SEER) program comparison of adult and pediatric Wilms’ tumor, Cancer 118(9):2541–2551, 2012.
Beckwith JB: Nephrogenic rests and the pathogenesis of wilms tumor: developmental and clinical considerations, Am J Med Genet 79:268–273, 1998.
Breslow N, Olshan A, Beckwith JB, Green DM: Epidemiology of WIms tumor, Med Pediatr Oncol 21:172–181, 1993.
Chagtai T, Zill C, Dainese L, et al: Gain of 1q as a prognostic biomarker in wilms tumors (WTs) treated with preoperative chemotherapy in the international society of paediatric oncology (SIOP) WT 2001 trial: a SIOP renal tumours biology consortium study, J Clin Oncol 34(26):3195–3203, 2016.
Davidoff AM: Wilms tumor, Adv Pediatr 59:247–267, 2012. D’Angio GJ: The national wilms tumor study: a 40 year perspective, Lifetime Data Anal 13:463–470, 2007.
Dome JS, Fernandez CV, Mullen EA, et al: Children’s oncology Group’s 2013 blueprint for research: renal tumors, Pediatr Blood Cancer 60(6):994–1000, 2013.
Dome JS, Graf N, Geller JI, et al: Advances in wilms tumor treatment and biology: progress through international collaboration, J Clin Oncol 33(27):2999–3007, 2015.
England RJ, Haider N, Vujanic GM, et al: Mesoblastic nephroma: a report of the United Kingdom Children’s cancer and leukaemia group (CCLG), Pediatr Blood Cancer 56(5):744–748, 2011.
Foulkes WD, et al: Extending the phenotypes associated with DICER1 mutations, Hum Mutat 32:1381–1384, 2011.
Fukuzawa R, Heathcott RW, More HE, Reeve AE: Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated wilms tumours: two case studies, J Clin Pathol 60:1013–1016, 2007.
Geller JI, Ehrlich PF, Cost NG, et al: Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children’s oncology group study AREN03b2, Cancer 121(14):2457–2464, 2015.
Gooskens SL, Houwing ME, Vujanic GM, et al: Congenital mesoblastic nephroma 50 years after its recognition: a narrative review, Pediatr Blood Cancer 64(7):2017.
Gratias EJ, Dome JS, Jennings LJ, et al: Association of chromosome 1q gain with inferior survival in favorable-histology wilms tumor: a report from the Children’s oncology group, J Clin Oncol 34(26):3189–3194, 2016.
Green DM: The evolution of treatment for wilms tumor, J Pediatr Surg 48:14–19, 2013.
Grundy PE, Breslow NE, Li S, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology wilms tumor: a report from the national wilms tumor study group, J Clin Oncol 23(29):7312–7321, 2005.
Hu Q, Gao F, Tian W, et al: Wt1 ablation and igf2 upregulation in mice result in wilms tumors with elevated ERK1/2 phosphorylation, J Clin Invest 121:174–183, 2011.
Huff V: Wilms tumor genetics, Am J Med Genet 79:260–267, 1998.
Kaste SC, Dome JS, Babyn PS, et al: Wilms tumour: prognostic factors, staging, therapy and late effects, Pediatr Radiol 38:2–17, 2008.
Khanna G, Rosen N, Anderson JR, et al: Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with wilms tumor: a report from the Children’s oncology group, Pediatr Blood Cancer 58(4):551–555, 2012.
Lange JM, Takashima JR, Peterson SM, et al: Breast cancer in female survivors of wilms tumor: a report from the national wilm tumor late effects study, Cancer 120:3722–3730, 2014.
Palculict TB, Ruteshouser EC, Fan Y, et al: Identification of germline DICER1 mutations and loss of heterozygosity in familial wilms tumour, J Med Genet 53:385–388, 2016.
Pritchard-Jones K, Bergeron C, de Camargo B, et al: Omission of doxorubicin from the treatment of stage II–III, intermediate-risk wilms tumour (SIOP WT 2011): an open-label, non-inferiority, randomized controlled trial, Lancet 386:1156–1164, 2015.
Pritchard-Jones K, Pritchard J: Success of clinical trials in childhood Wilms’ tumour around the world, Lancet 364:1468–1470, 2004.
Rakheja D, Chen KS, Liu Y, et al: Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in wilms tumor, Nat Commun 4:4802, 2014.
Rialon KL, Gulack BC, Englum BR, et al: Factors impacting survival in children with renal cell carcinoma, J Pediatr Surg 50(6):1014–1018, 2015.
Sajithlal G, Zou D, Silvius D, Xu P-X: Eya1 acts as a critical regulator for specifying the metanephric mesenchyme, Dev Biol 284:323–336, 2005.
Schaub R, Burger A, Bausch D, et al: Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in wilms tumors, Cancer Genet Cytogenet 127:61–65, 2007.
Scott RH, Douglas J, Baskcomb L, et al: Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic wilms tumor, Nat Genet 40:1329–1334, 2008.
Self M, Lagutin OV, Bowling B, et al: Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney, EMBO J 25:5214–5228, 2006.
Shamberger RC, Anderson JR, Breslow NE, et al: Long-term outcomes for infants with very low risk wilms tumor treated with surgery alone in national wilms tumor Study-5, Ann Surg 251(3):555–558, 2010.
Sonn G, Shortliffe LM: Management of wilms tumor: current standard of care, Nat Clin Pract Urol 5:551–560, 2008.
Syed JS, Nguyen KA, Wu CQ, et al: Distinguishing pediatric and adolescent renal cell carcinoma from other renal malignancies, Pediatr Blood Cancer 64(5):2017.
Tomlinson GE, Breslow NE, Dome J, et al: Rhabdoid tumor of the kidney in the national Wilms’ tumor study: age at diagnosis as a prognostic factor, J Clin Oncol 23(30):7641–7645, 2005.
Torrezan GT, Ferreira EN, Nakahata AM, et al: Recurrent somatic mutation in DROSHA induces microRNA profile changes in wilms tumour, Nat Commun 5:4039, 2014.
Urbach A, Yermalovich A, Zhang J, et al: Lin28 sustains early renal progenitors and induces wilms tumor, Genes Dev 28:971–982, 2014.
Walz AL, Ooms A, Gadd S, et al: Recurrent DGCR8, DROSHA, and six homeodomain mutations in favorable histology wilms tumors, Cancer Cell 27:286–297, 2015.
Wegert K, Osjaqie N, Vardapour R, et al: Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type wilms tumor, Cancer Cell 27:298–311, 2015.
Williams RD, Chagtai T, Alcaide-German M, et al: Multiple mechanisms of MYCN dysregulation in wilms tumour, Oncotarget 6:7232–7343, 2015.
Xu J, Wong EYM, Cheng C, et al: Eya1 interacts with six2 and myc to regulate expansion of the nephron progenitor pool during nephrogenesis, Dev Cell 31:434–447, 2014.
Anderson JL, Denny CT, Tap WD, et al: Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities, Pediatr Res 72(2):112–121, 2012.
Hawkins DS, Gupta AA, Rudzinski ER: What is new in the biology and treatment of pediatric rhabdomyosarcoma?, Curr Opin Pediatr 26(1):50–56, 2014.
Parham DM, Alaggio R, Coffin CM: Myogenic tumors in children and adolescents, Pediatr Dev Path 15(1):S211–S236, 2012.
Bielack S, Smeland S, Whelan J, et al: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial, J Clin Oncol 33:2279–2287, 2015.
Bishop MW, Janeway KA, Gorlick R: Future directions in the treatment of osteosarcoma, Curr Opin Pediatr 28(1):26–33, 2016.
Boyce AM, Kelly MH, Brillante BA, et al: A randomized, double blind, placebocontrolled trial of alendronate treatment for fibrous dysplasia of bone, J Clin Endocrinol Metab 99:4133–4140, 2014.
Gorlick R, Janeway K, Lessnick S, et al: Children’s oncology Group’s 2013 blueprint for research: bone tumors, Pediatr Blood Cancer 60:1009–1015, 2013.
Hart JL, Edgar MA, Gardner JM: Vascular tumors of bone, Semin Diagn Pathol 31:30–38, 2014.
Haupt R, Minkov M, Astigarraga I, et al: Langerhans cell histiocytosis: guidelines for diagnosis, clinical workup and treatment for patients till the age of 18 years, Pediatr Blood Cancer 60:175–184, 2013.
Marina N, Smeland S, Bielack S, et al: Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial, Lancet Oncol 17:1396–1408, 2016.
Pavone V, Caff G, Di Silvestri C, et al: Steroid injections in the treatment of humeral unicameral bone cysts: long-term follow-up and review of the literature, Eur J Orthop Surg Traumatol 24:497–503, 2014.
Roach JW, Klatt JW, Faulkner ND: Involvement of the spine in patients with multiple hereditary exostoses, J Bone Joint Surg Am 91:1942–1948, 2009.
Shiels WE 2nd, Beebe AC, Mayerson JL: Percutaneous doxycycline treatment of juxtaphyseal aneurysmal bone cysts, J Pediatr Orthop 36:205–212, 2016.
van IJzendoorn DGP, Bovee JVMG: Vascular tumors of bone: the evolvement of a classification based on molecular developments, Surg Pathol Clin 10:621–635, 2017.
Wright JG, Yandow S, Donaldson S, et al: A randomized clinical trial comparing intralesional bone marrow and steroid injections for simple bone cysts, J Bone Joint Surg Am 90:722–730, 2008.
Abramson DH, Fabius AW, Fancis JH, et al: Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma, Ophthalmic Genet 38:16–21, 2017.
Benavente CA, Dyer MA: Genetics and epigenetics of human retinoblastoma, Annu Rev Pathol 10:547–562, 2015.
Gunduz K, M?fl?oglu O, G?nalp I, et al: Metastatic retinoblastoma: clinical features, treatment, and prognosis, Ophthalmology 113:1558–1566, 2006.
Kleinerman RA, Yu CL, Little MP, et al: Variation of second cancers risk by family history of retinoblastoma among long-term survivors, J Clin Oncol 30:950–957, 2012.
Shields SL, Lally SE, Leahey AM, et al: Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy, Curr Opin Ophthalmol 25(5):374–385, 2014.
Billmire DF, Cullen JW, Rescorla FJ, et al: Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s oncology group, J Clin Oncol 32(5):465–470, 2014.
Frazier AL, Hale JP, Rodriguez-Galindo C, et al: Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States, J Clin Oncol 33:195–201, 2015.
Hanna NH, Einhorn LH: Testicular cancer — discoveries and updates, N Engl J Med 371:2005–2014, 2014.
Heravi-Moussavi A, Anglesio MS, Cheng SWG, et al: Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers, N Engl J Med 366:234–242, 2012.
Kremer MEB, Derikz JPM, van Baren R, et al: Patient-reported defecation and micturition problems among adults treated for sacrococcygeal teratoma during childhood — the need for new surveillance strategies, Pediatr Blood Cancer 63(4) 690–694, 2016.
Lakhoo K: Neonatal teratomas, Early Hum Dev 86(10):643–647, 2010.
Litchfield K, Shipley J, Turnbull C: Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application, Andrology 3(1):34–46, 2015.
Pashankar F, Hale JP, Dang H, et al: Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the malignant germ cell tumor international collaborative, Cancer 122:230–237, 2016.
Raypert-De Meyts E, McGlynn KA, Okamoto K, et al: Testicular germ cell tumours, Lancet 387:1762–1770, 2016.
Rescorla FJ, Ross JH, Billmire DF, et al: Surveillance after initial surgery for stage I pediatric and adolescent boys with malignant testicular germ cell tumors: report from the Children’s oncology group, J Pediatr Surg 50(6):1000–1003, 2015.
Schultz KAP, Schneider DT, Pashankar F, et al: Management of ovarian and testicular sex cord–stromal tumors in children and adolescents, J Pediatr Hematol Oncol 34:S55–S63, 2012.
Zhang M, Jiang W, Li G, et al: Ovarian masses in children and adolescents: an analysis of 521 clinical cases, J Pediatr Adolesc Gynecol 27:e73–e77, 2014.
Czauderna P, Lopez-Terrada D, Hiyama E, et al: Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy, Curr Opin Pediatr 26(1):19–28, 2014.
Knox JJ, Cleary SP, Dawson LA: Localized and systemic approaches to treating hepatocellular carcinoma, J Clin Oncol 33(16):1835–1844, 2015.
Habrand JL, Nehme D, Kalifa C, et al: Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcionmas in clildren?, Int J Radiat Oncol Biol Phys 23:525–531, 1992.
Liovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma, N Engl J Med 359:378–390, 2008.
Meyers RL, Tiao G, de Ville de Goyet J, et al: Hepatoblastoma state of the art: pretreatment extent of disease, surgical resection guidelines and the role of liver transplantation, Curr Opin Pediatr 26(1):29–36, 2014.
Meyers RL, Maibach R, Hiyama E, et al: Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s hepatic tumors international collaboration, Lancet Oncol 18:122–131, 2017.
Murawski M, Weeda VB, Maibach R, et al: Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies, J Clin Oncol 34(10):1050–1056, 2016.
Pham TA, Gallo AM, Concepcion W, et al: Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer, JAMA Surg 150(12):1150–1158, 2015.
Riggle KM, Turnham R, Scott JD, et al: Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma, Pediatr Blood Cancer 63(7):1163–1167, 2016.
Hoeger PH, Harper JI, Baselga E, et al: Treatment of infantile haemangiomas: recommendations of a European expert group, Eur J Pediatr 174(7):855–865, 2015.
Laaute-Labruze C, Hoeger P, Mazereeuw-Hautier J, et al: A randomized, controlled trial of oral propranolol in infantile hemangioma, N Engl J Med 372(8):735–746, 2015.
O’Rafferty CO, O’Regan GM, Irvine AD, et al: Recent advances in the pathobiology and management of Kasabach-merritt phenomenon, Br J Haematol 171(1):38–51, 2015.
Bagrodia N, Defnet AM, Kandal JJ: Management of lymphatic malformations in children, Curr Opin Pediatr 27(3):356–363, 2015.
Brauckhoff M, Machens A, Hess S, et al: Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis, Surgery 144:1044–1050, discussion 1050–1053, 2008.
Dermody S, Walls A, Harley EH Jr: Pediatric thyroid cancer: an update from the SEER database 2007–2012, Int J Pediatr Otorhinolaryngol 89:121–126, 2016.
Fagin JA, Wells SA Jr: Biologic and clinical perspectives on thyroid cancer, N Engl J Med 375(11):1054–1066, 2016.
Francis GL, Waguespack SG, Bauer AJ, et al: Management guidelines for children with thyroid nodules and differentiated thyroid cancer, Thyroid 25:716–759, 2015.
Tracy ET, Roman SA: Current management of pediatric thyroid disease and differentiated thyroid cancer, Curr Opin Oncol 28:37–42, 2016.
Waguespack SG, Rich TA, Perrier ND, et al: Management of medullary thyroid carcinoma and MEN2 syndromes in childhood, Nat Rev Endocrinol 7:596–607, 2011.
Wells SA Jr, Asa SL, Dralle H, et al: Revised American thyroid association guidelines for the management of medullary thyroid carcinoma, Thyroid 25:567–610, 2015.
Blandard P, Lee A, Marguet S, et al: Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis, Lancet Oncol 16(6):645–655, 2015.
Liu L-T, Tang L-Q, Chen Q-Y, et al: The prognostic value of plasma Epstein-barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma, Int J Radiat Oncol Biol Phys 93(4):862–869, 2015.
Sun Y, Li W-F, Chen N-Y, et al: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial, Lancet Oncol 17(11):1509–1520, 2016.
Goldberg J, Furman WL: Management of colorectal carcinoma in children and young adults, J Pediatr Hematol Oncol 34:S76–S79, 2012.
Jo WS, Chung DC: Genetics of hereditary colorectal cancer, Semin Oncol 32:11–23, 2012.
Poles GC, Clark DE, Mayo SW, et al: Colorectal carcinoma in pediatric patients: a comparison with adult tumors, treatment and outcomes from the national cancer database, J Pediatr Surg 51:1061–1066, 2016.
Sultan I, Rodriguez-Galindo C, El-Taani H, et al: Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases, Cancer 116:758–765, 2010.
Babic B, Patel D, Aufforth R, et al: Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors, Surgery 161:220–227, 2017.
Faillot S, Assie G: Endocrine tumours: the genomics of adrenocortical tumors, Eur J Endocrinol 174:R249–R265, 2016.
Mihai R: Rare adrenal tumors in children, Semin Pediatr Surg 23:71–75, 2014.
Roman-Gonzalez A, Jimenez C: Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials, Curr Opin Endocrinol Diabetes Obes 24(3):174–183, 2017.
Sakoda A, Mushtaq I, Levitt G, Sebire NJ: Clinical and histopathological features of adrenocortical neoplasms in children: retrospective review from a single specialist center, J Pediatr Surg 49:410–415, 2014.
Cook RJ, Wang Z, Arora M, et al: Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis, Bone Marrow Transplant 47:1455–1458, 2014.
Dufresne A, Cassier P, Couraud L, et al: Desmoplastic small round cell tumour: current management and recent findings, Sarcoma 714986:2012, 2012.
Hayes-Jordan A, Green HL, Lin H, et al: Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor, Ann Surg Oncol 21:220–224, 2014.
Honore C, Amroun K, Vilcot L, et al: Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option, Ann Surg Oncol 22:1073–1079, 2015.
Allen CE, Ladisch S, McClain KL: How I treat langerhans cell histiocytosis, Blood 126(1):26–35, 2015.
Allen CE, Li L, Peters TL, et al: Cell-specific gene expression in langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal langerhans cells, J Immunol 184(8):4557–4567, 2010.
Badalian-Very G, Vergilio JA, Degar BA, et al: Recurrent BRAF mutations in langerhans cell histiocytosis, Blood 116(11):1919–1923, 2010.
Battistella M, Fraitag S, Teillac DH, et al: Neonatal and early infantile cutaneous langerhans cell histiocytosis, Arch Dermatol 146:149–156, 2010.
Broadbent V, Gadner H, Komp DM, et al: Histiocytosis syndromes in children. II. Approach to the clinical and laboratory evaluation of children with langerhans cell histiocytosis. Clinical writing group of the histiocyte society, Med Pediatr Oncol 17(6):492–495, 1989.
Chakraborty R, Hampton OA, Shen X, et al: Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis, Blood 124(19):3007–3015, 2014.
Chan JKC, Lamant L, Algar E, et al: ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy, Blood 112(7):2965–2967, 2008.
Coury F, Annels N, Rivollier A, et al: Langerhans cell histiocytosis reveals a new IL-17a-dependent pathway of dendritic cell fusion, Nat Med 14:81–87, 2008.
Ehrhardt MJ, Humphrey SR, Kelly ME, et al: The natural history of skin-limited langerhans cell histiocytosis: a single-institution experience, J Pediatr Hematol Oncol 36(8):613–616, 2014.
Gadner H, Minkov M, Grois N, et al: Therapy prolongation improves outcome in multisystem langerhans cell histiocytosis, Blood 121:5006–5014, 2013.
Grois N, Fahrner B, Arceci RJ, et al: Central nervous system disease in langerhans cell histiocytosis, J Pediatr 156(6):873–881, 2010.
Lau S, Chu P, Weiss M: Immunohistochemical expression of langerin in langerhans cell histiocytic disorders, Am J Surg Pathol 32:615–619, 2008.
Minkov M, Steiner M, Potschger U, et al: Reactivations in multisystem langerhans cell histiocytosis: data of the international LCH registry, J Pediatr 153:700–705, 2008.
Ronceray L, P?tschger U, Janka G, et al: Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: effect on course and outcome, J Pediatr 161(1):129–133, e1–3, 2012.
Schmitt AR, Wetter DA, Camilleri MJ, et al: Langerhans cell histiocytosis presenting as a blueberry muffin rash, Lancet 390:155, 2017.
Simko SJ, Garmezy B, Abhyankar H, et al: Differentiating skin-limited and multisystem langerhans cell histiocytosis, J Pediatr 165:990–996, 2014.
Wnorowski M, Prosch H, Prayer D, et al: Pattern and course of neurodegeneration in langerhans cell histiocytosis, J Pediatr 153:127–132, 2008.
Bode SFN, Bogdan C, Beutel K, et al: Hemophagocytic lymphohistiocytosis in imported pediatric visceral leishmaniasis in a nonendemic area, J Pediatr 165:147–153, 2014.
Brisse E, Wouters CH, Matthys P: Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders, Cytokine Growth Factor Rev 26:263–280, 2015.
Canna SW, Behrens EM: Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes, Pediatr Clin North Am 59:329–344, 2012.
Cetica V, Sieni E, Pende D, et al: Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry, J Allergy Clin Immunol 137:188–196, 2016.
Chandrakasan S, Filipovich AH: Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment, J Pediatr 163(5):1253–1259, 2013.
Cheng A, Williams F, Fortenberry J, et al: Use of extracorporeal support in hemophagocytic lymphohistiocytosis secondary to ehrlichiosis, Pediatrics 138(4):e20154176, 2016.
Deiva K, Mahlaoui N, Beaudonnet F, et al: CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis, Neurology 78:1150–1156, 2012.
Diamond EL, Durham BH, Haroche J: Diverse and targetable kinase alterations drive histiocytic neoplasms, Cancer Discov 6(2):154–165, 2016.
Guandalini M, Butler A, Mandelstam S: Spectrum of imaging appearances in Australian children with central nervous system hemophagocytic lymphohistiocytosis, J Clin Neurosci 21:305–310, 2014.
Hara S, Kawada J, Kawano Y, et al: Hyperferritinemia in neonatal and infantile human parechovirus-3 infection in comparison with other infectious diseases, J Infect Chemother 20:15–19, 2014.
Henter JI, Horne A, Aric? M, et al: HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, Pediatr Blood Cancer 48(2):124–131, 2007.
Horne AC, Trottestam H, Arico M, et al: Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis, Br J Haematol 140:327–335, 2007.
Janka GE: Familial and acquired hemophagocytic lymphohistiocytosis, Annu Rev Med 63:233–246, 2012.
Kaufman KM, Linghu B, Szustakowski JD, et al: Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis, Arth Rheum 66(12):3486–3495, 2014.
Lehmberg K, Ehl S: Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis, Br J Haematol 160:275–287, 2013.
Lehmberg K, Pink I, Eulenburg C, et al: Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis, J Pediatr 162(6):1245–1251, 2013.
Mahlaoui N, Iuachee-Chardin M, de Saint Basile G, et al: Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients, Pediatrics 120:e622–e628, 2007.
Mischler M, Fleming GM, Shanley TP, et al: Epstein-barr virus–induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit, Pediatrics 119:e1212–e1218, 2007.
Ouachee-Chardin M, Elie C, de Saint Basile G, et al: Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients, Pediatrics 117:e743–e750, 2006.
Rajasekaran S, Kruse K, Kovey K, et al: Therapeutic role of anakinra, and interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children, Pediatr Crit Care Med 15:401–408, 2014.
Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al: Adult haemophagocytic syndrome, Lancet 383:1503–1514, 2014.
Risma K, Jordan MB: Hemophagocytic lymphohistiocytosis: updates and evolving concepts, Curr Opin Pediatr 24(1):9–15, 2012.
Rudman Spergel A, Walkovich K, Price S, et al: Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis, Pediatrics 132(5):e1440–e1444, 2013.
Schulert GS, Zhang M, Husami NF, et al: Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of h1n1 influenza, J Infect Dis 213:1180–1188, 2016.
Sharp TM, Gaul L, Muehlenbachs A, et al: Centers for disease control and prevention (CDC). Fatal hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection — new Mexico and texas, 2012, MMWR 63(3):49–54, 2014.
Trottestam H, Horne A, Aric? M, et al: Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol, Blood 118(17):4577–4584, 2011.
Valentine G, Thomas TA, Nguyen T, et al: Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report, Pediatrics 134:e1727–e1730, 2014.
Weitzman S: Approach to hemophagocytic syndromes, Hematology Am Soc Hematol Educ Program 2011:178–183, 2011.
Dehner LP: Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations, Am J Surg Pathol 29(1):579–593, 2005.
Emile JF, Abla O, Fraitag S, et al: Histiocyte society: revised classification of histiocytoses and neoplasms of the macrophage–dendritic cell lineages, Blood 127:2672–2681, 2016.
Pulsoni A, Anghel G, Falcucci P, et al: Treatment of sinus histiocytosis with massive lymphadenopathy (rosai-dorfman disease): report of a case and literature review, Am J Hematol 69(1):67–71, 2002.
Weitzman S, Weitzman S, Jaffe R: Uncommon histiocytic disorders: the non–langerhans cell histiocytoses, Pediatr Blood Cancer 45(3):256–264, 2005.
